Please login to the form below

interferon beta-1a

This page shows the latest interferon beta-1a news and features for those working in and with pharma, biotech and healthcare.

Ocrevus off to a flying start as Roche raises 2017 forecasts

The take-up of the drug has been buoyed by trials showing that the drug outperformed Merck KGaA's MS stalwart Rebif (interferon beta-1a) in two relapsing MS phase III

Latest news

Roche sets disruptive price for new MS drug Ocrevus in US

Ocrevus' clinical profile has already caught the attention of MS patients and their doctors, with trials showing that the drug outperformed Merck KGaA's Rebif (interferon beta-1a) in two relapsing
Avelumab costs peg back profit at Merck KGaA

Pfizer-partnered avelumab is central to Merck's plans to revitalise its healthcare business, currently under pressure as top-selling Rebif (interferon beta-1a) - an injectable treatment for multiple sclerosis - tries
FDA delays verdict on Roche's MS drug Ocrevus

Ocrevus is the first investigational medicine with the potential to treat both forms, outperforming Merck KGaA's Rebif (interferon beta-1a) in the two relapsing multiple sclerosis phase III trials and
Merck's pharma unit faces tougher 2017 as fertility boost recedes

2017". That's important because Gonal-f has buoyed Merck's healthcare unit in the face of declining sales for its two biggest products - injectable multiple sclerosis therapy Rebif (interferon ... 1a) and colorectal cancer therapy Erbitux (cetuximab) -
Fertility drugs drive healthcare growth at Merck KGaA

Merck makes the most of its portfolio of mature drugs, and top-seller Rebif (interferon beta-1a) for relapsing-remitting multiple sclerosis held up fairly well despite fierce competition from newer,

More from news
Approximately 1 fully matching, plus 50 partially matching documents found.

Latest Intelligence

Tackling a formidable foe

Formidable foe. “With Rebif (interferon beta-1a), Merck’s legacy MS therapy approved in Europe 20 years ago, one of the innovations is the ability to have auto-injectors and devices

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager – Healthcare advertising: Salary TBC

Client Services Director- Flexible Working: Negotiable

Account Director – UK Office: Excellent salary and benefits

Senior Medical Writer: Competitive salary plus benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Events Executive: DOE

Subscribe to our email news alerts

PMHub

Add my company

JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...